Emerging Therapies Using Microbiome-Derived Metabolites for Chronic Inflammatory Skin Disorders

Abstract

Chronic inflammatory skin disorders, such as atopic dermatitis, psoriasis, and hidradenitis suppurativa, present significant therapeutic challenges due to their relapsing nature, multifactorial pathogenesis, and the frequent adverse effects or limited efficacy of conventional treatments. Recent advances in understanding the human microbiome and its metabolites have revealed novel mechanisms by which cutaneous and gut microbiota regulate skin immunity and inflammation. This review examines the evolving evidence on microbiome-derived metabolites as emerging therapeutic agents in chronic dermatological inflammation, exploring their mechanistic roles, translational potential, and the implications for clinical practice. The discussion highlights key recent findings, risk-benefit considerations, and future directions in this rapidly developing field.

Introduction

Chronic inflammatory skin disorders encompass a spectrum of diseases characterized by immune dysregulation, persistent inflammation, and significant patient morbidity. Traditional management strategies target symptomatic relief or broad immunosuppression, often with variable results. The expanding research on the skin and gut microbiome has shifted attention toward the role of microbial metabolites in immune homeostasis and cutaneous health. These small molecules, including short-chain fatty acids, tryptophan metabolites, and secondary bile acids, exert profound immunomodulatory effects and are increasingly recognized as both biomarkers and potential therapeutic agents. This article provides an in-depth review of the clinical burden, underlying mechanisms, and recent advances in utilizing microbiome-derived metabolites as innovative treatments for chronic inflammatory skin disorders.

Epidemiology / Disease Burden

Chronic inflammatory skin disorders are among the most prevalent dermatological conditions globally. Atopic dermatitis affects up to 20% of children and 3% of adults in industrialized nations, while psoriasis impacts approximately 2–3% of the worldwide population. Hidradenitis suppurativa, though less common, substantially impairs quality of life due to pain and scarring. These conditions confer considerable psychosocial and economic burdens, with frequent relapses, reduced work productivity, and increased healthcare utilization. The chronicity and co-morbid associations with systemic diseases, such as metabolic syndrome and depression, underscore the need for novel, sustainable therapies with improved safety profiles.

Pathophysiology

The pathogenesis of chronic inflammatory skin disorders is multifactorial, involving genetic predisposition, environmental triggers, immune dysfunction, and, crucially, alterations in the skin and gut microbiome. Dysbiosis characterized by reduced microbial diversity and pathogenic species overgrowth disrupts cutaneous homeostasis and promotes aberrant immune responses. Microbiome-derived metabolites act as key signaling molecules, modulating epithelial barrier integrity, T-cell differentiation, and cytokine production. For example, short-chain fatty acids (SCFAs) such as butyrate and propionate maintain regulatory T cell function and inhibit pro-inflammatory pathways, while tryptophan catabolites activate aryl hydrocarbon receptor (AHR) signaling to suppress Th17-driven inflammation. Disruption in these metabolite-mediated pathways has been implicated in the persistence and severity of inflammatory dermatoses.

Risk Factors

Genetic susceptibility, environmental exposures (pollution, allergens, antibiotics), diet, and lifestyle factors shape both disease risk and microbiome composition. Broad-spectrum antibiotic use is a well-established risk factor for dysbiosis and subsequent flares in atopic dermatitis and psoriasis. Westernized diets, low in fiber and high in saturated fats, decrease SCFA-producing commensals and potentiate systemic inflammation. Obesity, metabolic syndrome, and psychological stress further contribute to dysbiosis and disease exacerbation. Understanding these risk factors is essential for preventive strategies and optimizing the therapeutic impact of microbiome-derived interventions.

Clinical Features

Chronic inflammatory skin disorders typically present with recurrent, relapsing lesions characterized by erythema, scaling, pruritus, and, in severe cases, lichenification or suppuration. Atopic dermatitis manifests with flexural eczema and intense itch, while psoriasis is distinguished by well-demarcated plaques and silvery scales. Hidradenitis suppurativa features painful nodules, abscesses, and sinus tract formation, often in intertriginous areas. The chronicity and visibility of these conditions significantly impact patient well-being, with frequent comorbidities including anxiety, depression, and cardiovascular risk factors.

Diagnosis

Diagnosis is predominantly clinical, supported by patient history, morphology of lesions, and exclusion of secondary causes. Biomarkers such as serum IgE (in atopic dermatitis) and inflammatory cytokines (e.g., TNF-α, IL-17) may assist in disease stratification but lack specificity. Recent advances in multi-omic profiling, including metagenomics and metabolomics, have enabled the identification of disease-specific microbial signatures and metabolite profiles, offering potential for personalized diagnosis and monitoring.

Treatment & Management

Conventional therapies include topical corticosteroids, calcineurin inhibitors, phototherapy, and systemic agents such as methotrexate, cyclosporine, and biologics targeting TNF, IL-4, IL-13, or IL-17 pathways. While effective in many cases, these treatments are associated with adverse effects, limited long-term safety, and the risk of tachyphylaxis. Adjunctive strategies such as emollients, antihistamines, and lifestyle modification remain cornerstones of comprehensive care. However, the need for safer, more targeted therapies has driven interest in harnessing the therapeutic potential of the microbiome and its metabolites.

Recent Advances / Emerging Therapies

Microbiome-derived metabolites represent a cutting-edge therapeutic frontier. SCFAs, particularly butyrate, have demonstrated efficacy in preclinical models by enhancing skin barrier function, suppressing NF-κB signaling, and promoting regulatory T-cell responses. Topical and oral formulations of SCFAs are being evaluated in early-phase clinical trials for atopic dermatitis and psoriasis, with promising safety and efficacy profiles. Tryptophan metabolites, such as indole-3-aldehyde, modulate AHR signaling and downregulate Th17-mediated inflammation, with topical AHR agonists (e.g., tapinarof) recently approved for psoriasis. Secondary bile acids, produced by commensal gut bacteria, show potential in dampening systemic inflammation via FXR and TGR5 receptor pathways. Fecal microbiota transplantation and engineered probiotics designed to deliver beneficial metabolites are also under investigation, though long-term data are pending. These therapies offer the advantage of modulating disease pathways at multiple levels, with the potential for disease modification and fewer systemic adverse effects.

Guideline Recommendations

While current guidelines for chronic inflammatory skin disorders emphasize established pharmacologic and non-pharmacologic modalities, expert consensus is evolving to incorporate the role of microbiome modulation. The American Academy of Dermatology and European guidelines acknowledge the potential of microbiome-based interventions but recommend their use within clinical trial settings until further high-quality evidence is available. Ongoing studies and future guideline updates are expected to clarify indications, dosing, and safety profiles as the evidence base matures.

Conclusion

The rapid evolution of microbiome science has unveiled a new paradigm in the management of chronic inflammatory skin disorders. Microbiome-derived metabolites offer targeted, mechanism-based approaches to restoring immune balance and skin homeostasis. Early clinical results are encouraging, but further large-scale, randomized trials are necessary to determine long-term efficacy, safety, and optimal integration into clinical practice. Vigilant patient selection, monitoring, and interdisciplinary collaboration will be key to translating these promising therapies from bench to bedside. As our understanding deepens, microbiome-derived interventions may redefine the therapeutic landscape for chronic inflammatory dermatoses.